Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
CSJ117 - Inhaled TSLP inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04410523 (CCSJ117A12201C)
Asthma
Phase 2
625
Pre-dose FEV1 (Forced Expiratory Volume in 1 second) change from baseline after
12 weeks of treatment. Average change from baseline in pre-dose FEV1 at week 8
& week 12
CSJ117 0.5mg
CSJ117 1mg
CSJ117 2 mg
CSJ117 4 mg
CSJ117 8 mg
Placebo
Asthma patients on background medium or high ICS plus LABA therapy
Target Patients
Read-out Milestone(s)
Publication
2023
2023
111 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation